Compare TRUP & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRUP | CMPX |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.7M | 927.5M |
| IPO Year | 2014 | 2020 |
| Metric | TRUP | CMPX |
|---|---|---|
| Price | $21.88 | $2.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $45.80 | $14.57 |
| AVG Volume (30 Days) | 351.5K | ★ 4.6M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 295.65 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $1,439,305,000.00 | N/A |
| Revenue This Year | $11.79 | N/A |
| Revenue Next Year | $8.83 | $934.41 |
| P/E Ratio | $200.00 | ★ N/A |
| Revenue Growth | ★ 11.95 | N/A |
| 52 Week Low | $21.16 | $1.61 |
| 52 Week High | $57.35 | $6.88 |
| Indicator | TRUP | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 37.38 |
| Support Level | $21.16 | $1.68 |
| Resistance Level | $29.24 | $2.47 |
| Average True Range (ATR) | 0.94 | 0.16 |
| MACD | 0.10 | 0.12 |
| Stochastic Oscillator | 34.80 | 41.62 |
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions. Geographically, the company operates in United States, which derives maximum revenue; and Canada and Others.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.